Association Between HLA genotypes and Oxcarbazepine-induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-Analysis

被引:0
|
作者
Tangamornsuksan, Wimonchat [1 ,3 ]
Scholfield, C. N. [1 ,3 ]
Lohitnavy, Manupat [1 ,2 ,3 ]
机构
[1] Naresuan Univ, Fac Pharmaceut Sci, Ctr Excellence Environm Hlth & Toxicol, Phitsanulok, Thailand
[2] Naresuan Univ, Fac Pharmaceut Sci, Pharmacokinet Res Unit, Phitsanulok, Thailand
[3] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharm Practice, Phitsanulok, Thailand
关键词
STEVENS-JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; RISK; ALLELE; HYPERSENSITIVITY; HLA-A-ASTERISK-31/01;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
PURPOSE: To systematically review and quantitatively synthesize associations between HLA genotypes and oxcarbazepine-induced cutaneous adverse drug reactions (OXC-cADRs), including Stevens-Johnson syndrome (SJS) and maculopapular rash. METHODS: Studies investigating associations between HLA genotypes and OXC-cADRs were systematically searched irrespective of language, in PubMed, HuGENet (Human Genome Epidemiology Network), and the Cochrane Library from their inception until January, 2017. Inclusion criteria were studies investigating associations between HLA genotypes and OXC-cADRs that reported sufficient data for calculating the frequency of HLA genotype carriers among cases and controls. Overall odds ratios (ORs) with corresponding 95% CIs were calculated using a random-effects model to determine the association between HLA genotypes and OXC-cADRs. RESULTS: The initial searches identified 91 articles, of which 6 studies met the selection criteria. The studies included 229 patients with OXC-cADRs, 251 OXC-tolerant patients, and 2,358 participants from general populations of Han Chinese, Korean, and Thai ethnicities. Associations between HLA-B*1502 and OXC-induced SJS were found in both the general population [OR=30.2 (95% CI=3.45-264)] and in OXC-tolerant individuals [OR=26.4 (95% CI=7.98-87.6)]. An association between the HLA-B*1502 and OXC-induced maculopapular rash was found in the general population [OR=5.67 (95% CI=2.03-15.9)] while HLA-A*3101 also associated with OXC-induced maculopapular rash [overall OR=29.2 (95% CI=6.70-128)]. CONCLUSIONS: Strong associations between the HLA-B*1502 and OXC-cADRs (SJS and maculopapular rash) were found in both controls from general population and OXC-tolerant groups. There was also an association between HLA-B*3101 and OXC-induced maculopapular rash. For patient safety, genetic screening especially for HLA-B*1502 prior to OXC therapy at least in these closely related ethnicities is warranted. Further studies need to better define other ethnicities at risk and a wider range of MHC gene subtypes.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 50 条
  • [21] Association between HLA-B*15:02 and carbamazepine induced severe cutaneous adverse drug reactions in Myanmar
    Khor, Amy Hui-Ping
    Aye, Seinn Mya Mya
    Lim, Kheng-Seang
    Aung, Yan Lynn
    Aye, Yin Minn
    Ohnmar
    Thit, Win Min
    Tan, Chong-Tin
    Ng, Ching-Ching
    NEUROLOGY ASIA, 2017, 22 (03) : 283 - 285
  • [22] Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole-Induced Severe Cutaneous Adverse ReactionsA Systematic Review and Meta-Analysis
    Wu, Po-Chien
    Chen, Wei-Ti
    Huang, I-Hsin
    Chen, Chun-Bing
    Wang, Chuang-Wei
    Tai, Cheng-Chen
    Chung, Wen-Hung
    Chi, Ching-Chi
    JAMA DERMATOLOGY, 2024, 160 (05) : 525 - 534
  • [23] Association between HLA gene polymorphism and cutaneous adverse reactions caused by antiepileptic drugs
    Zhang, Jingang
    Li, Xinrui
    Su, Yuanyuan
    Sun, Min
    Wang, Junbang
    Hao, Yunhua
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (04) : 3399 - 3403
  • [24] The HLA-B*15:02 polymorphism and Tegretol®-induced serious cutaneous reactions in epilepsy: An updated systematic review and meta-analysis
    Chouchi, M.
    Kaabachi, W.
    Tizaoui, K.
    Daghfous, R.
    Aidli, S. E.
    Hila, L.
    REVUE NEUROLOGIQUE, 2018, 174 (05) : 278 - 291
  • [25] Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis
    Deng, Qiancheng
    Zeng, Qinghai
    Jing, Chen
    Fang, Xia
    Lu, Jianyun
    Huang, Jinhua
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2017, 92 (03) : 345 - 349
  • [26] HLA-associated antiepileptic drug-induced cutaneous adverse reactions
    Mullan, Kerry A.
    Anderson, Alison
    Illing, Patricia T.
    Kwan, Patrick
    Purcell, Anthony W.
    Mifsud, Nicole A.
    HLA, 2019, 93 (06) : 417 - 435
  • [27] Genetic Association of Co-Trimoxazole-Induced Severe Cutaneous Adverse Reactions Is Phenotype-Specific: HLA Class I Genotypes and Haplotypes
    Sukasem, Chonlaphat
    Pratoomwun, Jirawat
    Satapornpong, Patompong
    Klaewsongkram, Jettanong
    Rerkpattanapipat, Ticha
    Rerknimitr, Pawinee
    Lertpichitkul, Pattamon
    Puangpetch, Apichaya
    Nakkam, Nontaya
    Konyoung, Parinya
    Khunarkornsiri, Usanee
    Disphanurat, Wareeporn
    Srisuttiyakorn, Chutika
    Pattanacheewapull, Oranuch
    Kanjanawart, Sirimas
    Kongpan, Thachanan
    Chumworathayi, Pansu
    Saksit, Niwat
    Bruminhent, Jackrapong
    Tassaneeyakul, Wichittra
    Chantratita, Wasun
    Pirmohamed, Munir
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (05) : 1078 - 1089
  • [28] Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies
    Chen, Wei-Ti
    Chi, Ching-Chi
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 1878 - 1887
  • [29] Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China
    Wu, X. T.
    Hu, F. Y.
    An, D. M.
    Yan, B.
    Jiang, X.
    Kwan, P.
    Stefan, H.
    Zhou, D.
    EPILEPSY & BEHAVIOR, 2010, 19 (03) : 405 - 408
  • [30] HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis
    Genin, E.
    Chen, D-P
    Hung, S-I
    Sekula, P.
    Schumacher, M.
    Chang, P-Y
    Tsai, S-H
    Wu, T-L
    Bellon, T.
    Tamouza, R.
    Fortier, C.
    Toubert, A.
    Charron, D.
    Hovnanian, A.
    Wolkenstein, P.
    Chung, W-H
    Mockenhaupt, M.
    Roujeau, J-C
    PHARMACOGENOMICS JOURNAL, 2014, 14 (03) : 281 - 288